4-羟基查耳酮

生物活性靶点体外研究体内研究 4-羟基查耳酮试剂级价格

4-羟基查耳酮

CAS号:2657-25-2
英文名:4'-HYDROXYCHALCONE
中文名:4-羟基查耳酮
CBNumber:CB1342383
分子式:C15H12O2
分子量:224.25
MOL File:2657-25-2.mol

4-羟基查耳酮化学性质

熔点 :174-178 °C
沸点 :419.6±45.0 °C(Predicted)
密度 :1.191±0.06 g/cm3(Predicted)
储存条件 :Inert atmosphere,Room Temperature
溶解度 :DMF: 30 mg/ml; DMSO: 30 mg/ml; Ethanol: 30 mg/ml; Ethanol:PBS (pH 7.2) (1:4): 0.2 mg/ml
形态 :powder to crystal
酸度系数(pKa) :7.72±0.15(Predicted)
颜色 :Light orange to Yellow to Green
BRN :2049150
InChIKey :UAHGNXFYLAJDIN-IZZDOVSWSA-N
LogP :3.650 (est)
CAS 数据库 :2657-25-2(CAS DataBase Reference)

安全信息

危险品标志 :Xi
危险类别码 :36/37/38
安全说明 :37/39-26-37
海关编码 :29145090

4-羟基查耳酮性质、用途与生产工艺

生物活性 4'-Hydroxychalcone (P-Cinnamoylphenol)，存在于草药、香料和茶叶中，是一种刺甘草查尔酮。它具有多种生物活性，能够抑制TNF-α诱导的NF-κB通路激活、并激活BMP信号通路。
靶点
Target Value
NF-κB
()

体外研究

4'-Hydroxychalcone (20-40 μM ; 2 hours) inhibits TNFα-induced (20 ng/mL; 6 hours) NF-kB pathway activation in a dose-dependent manner.
4'-Hydroxychalcone (0.1-25 μM ; 8 hours) inhibits proteasome activity in a dose-dependent manner but has no effect on IKK activity.
4'-Hydroxychalcone inhibits TNFα-dependent degradation of IkBα and subsequently prevents p50/p65 nuclear translocation leading to 4'-Hydroxychalcone-inhibited expression of NF-kB target genes.
4'-Hydroxychalcone affects cancer cell viability but has no significant effect on non-transformed cell viability.

Cell Viability Assay

Cell Line:	K562 cells, Jurkat cells, U937 cells, PBMCs
Concentration:	5 μM, 10 μM, 20 μM, 24 μM, 28 μM, 32 μM, 40 μM, 60 μM
Incubation Time:	24 hours
Result:	Affected cancer cell viability but has no significant effect on non-transformed cell viability.

Western Blot Analysis

Cell Line:	Jurkat cells
Concentration:	60 μM (followed by TNFα 20 ng/mL )
Incubation Time:	2 hours
Result:	Inhibited TNFα -dependent degradation of IkBα and prevents p50/p65 nuclear translocation.

体内研究

4'-Hydroxychalcone has hepatoprotective activity against Acetaminophen induced hepatotoxicity in mice.

Animal Model:	Male albino mice(5-30 g)
Dosage:	25 mg/kg, 50 mg/kg, 100 mg/kg
Administration:	Oral administration, 12h intervals, 4 doses
Result:	Significantly reduced the mortality rate induced by Acetaminophen (1 g/kg).